Navigation Links
Advanced Imaging Technologies to Limit Breast and GI Biopsy Procedures
Date:11/12/2008

Growth will continue to occur through 2013, according to Millennium Research Group

WALTHAM, Mass., Nov. 12 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Biopsy Devices 2009 report, the popularity of advanced imaging technologies will restrict the number of gastrointestinal (GI) and breast biopsy procedures performed through 2013.

The availability of endoscopes with microscopic capabilities for visualizing tissue at the cellular level has decreased the requirement for a biopsy in endoscopic GI procedures. PENTAX's Confocal Endomicroscope, for example, enables physicians to examine inner structures at extreme magnifications, in some cases allowing for diagnosis without the need for a biopsy. Should additional competitors enter the endomicroscopy market, unit growth for GI biopsy forceps will slow.

"Likewise, breast biopsy procedures will be affected by advanced imaging technologies," says Sarah Leonard, Analyst at MRG. "Improvements in breast imaging technology are leading to more accurate evaluations of suspected breast cancers, potentially reducing the need for breast biopsies. In particular, breast MRI, breast-specific gamma imaging, and positron emission mammography provide information that can help determine whether a suspicious lesion is benign or malignant, boosting the appeal of diagnostic breast imaging and slowing growth in the number of breast biopsies being performed. Nevertheless, physician fear of malpractice lawsuits and limited reimbursement for advanced imaging will prevent US breast and GI biopsy procedure volumes from declining in the next five years."

MRG's US Markets for Biopsy Devices 2009 report provides coverage of key industry competitors including Angiotech, Boston Scientific, Cardinal Health, ConMed, Cook Medical, C.R. Bard, Ethicon Endo-Surgery, Hologic, Olympus, PENTAX, SenoRx, and more.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net

Elizabeth Marshall

Decision Resources Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Launches New C-VUE(R) Advanced(TM) Custom Toric Lens
2. Philips Introduces New, Advanced Light Therapy Device to Offer Quick Relief from Winter Blues
3. Many Breast Cancer Patients Are Not Receiving Most Advanced Breast Conserving Surgical Techniques, New Study Finds
4. Top Indian Cancer Hospital to Introduce Advanced Radiosurgery Treatments With Novalis Tx from Varian Medical Systems and BrainLAB
5. Advanced Health Care Options for People With Diabetes
6. Doctors Test Advanced Tool for Treating Prostate Cancer
7. Relations PR & Marketing Named Agency of Record for Advanced Ultrasound Services
8. Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions
9. Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques
10. Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region
11. 27 National Nursing Organizations Join Together to Commission a Study of the Impact of Advanced Practice Registered Nurses on Healthcare Quality, Safety, and Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: